INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Participants must have completed 3 cycles of a     │ Participants must have completed 3 cycles of a     │     100 │
│ bortezomib-based induction regimen (as defined by  │ bortezomib-based induction regimen (as defined by  │         │
│ current NCCN guidelines) and have no evidence of   │ current NCCN guidelines) and have no evidence of   │         │
│ disease progression as defined by IMWG criteria    │ disease progression as defined by IMWG criteria    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants with light chain and free light chain │ Participants with light chain and free light chain │     100 │
│ (FLC) only may be enrolled if they meet all the    │ (FLC) only may be enrolled if they meet all the    │         │
│ criteria for a diagnosis of MM                     │ criteria for a diagnosis of MM                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants must be considered by their physician │ Participants must be considered by their physician │     100 │
│ eligible to receiving the IRD regimen              │ eligible to receiving the IRD regimen              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG)          │ Eastern Cooperative Oncology Group (ECOG)          │     100 │
│ performance status and/or other performance status │ performance status and/or other performance status │         │
│ 0, 1, or 2 at time of enrollment                   │ 0, 1, or 2 at time of enrollment                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in other interventional clinical     │ Participation in other interventional clinical     │     100 │
│ trials, including those with other investigational │ trials, including those with other investigational │         │
│ agents not included in this trial, within 30 days  │ agents not included in this trial, within 30 days  │         │
│ of the start of this trial and throughout the      │ of the start of this trial and throughout the      │         │
│ duration of this trial. Non-interventional trials  │ duration of this trial. Non-interventional trials  │         │
│ (that is, observational trials) are permitted at   │ (that is, observational trials) are permitted at   │         │
│ any time point                                     │ any time point                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgery within 14 days before enrollment     │ Major surgery within 14 days before enrollment     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Radiotherapy within 14 days before enrollment (if  │ Radiotherapy within 14 days before enrollment (if  │     100 │
│ the involved field is small, 7 days will be        │ the involved field is small, 7 days will be        │         │
│ considered a sufficient interval between treatment │ considered a sufficient interval between treatment │         │
│ and administration of the ixazomib)                │ and administration of the ixazomib.)               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Infection requiring systemic antibiotic therapy or │ Infection requiring systemic antibiotic therapy or │     100 │
│ other serious infection within 14 days before      │ other serious infection within 14 days before      │         │
│ study enrollment                                   │ study enrollment                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of current uncontrolled cardiovascular    │ Evidence of current uncontrolled cardiovascular    │     100 │
│ conditions, including uncontrolled hypertension,   │ conditions, including uncontrolled hypertension,   │         │
│ uncontrolled cardiac arrhythmias, symptomatic      │ uncontrolled cardiac arrhythmias, symptomatic      │         │
│ congestive heart failure, unstable angina, or      │ congestive heart failure, unstable angina, or      │         │
│ myocardial infarction within the past 6 months     │ myocardial infarction within the past 6 months     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic treatment, within 14 days before the      │ Systemic treatment, within 14 days before the      │     100 │
│ first dose of ixazomib, with strong cytochrome     │ first dose of ixazomib, with strong cytochrome     │         │
│ P450 3A (CYP3A) inducers (rifampin, rifapentine,   │ P450 3A (CYP3A) inducers (rifampin, rifapentine,   │         │
│ rifabutin, carbamazepine, phenytoin,               │ rifabutin, carbamazepine, phenytoin,               │         │
│ phenobarbital), or use of Ginkgo biloba or St.     │ phenobarbital), or use of Ginkgo biloba or St.     │         │
│ John's wort                                        │ John's wort                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ongoing or active systemic infection, active       │ Ongoing or active systemic infection, active       │     100 │
│ hepatitis B or C virus infection, or known human   │ hepatitis B or C virus infection, or known human   │         │
│ immunodeficiency virus positive                    │ immunodeficiency virus positive                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosed or treated for another malignancy within │ Diagnosed or treated for another malignancy within │     100 │
│ 2 years before study enrollment or previously      │ 2 years before study enrollment or previously      │         │
│ diagnosed with another malignancy and have any     │ diagnosed with another malignancy and have any     │         │
│ evidence of residual disease. Participants with    │ evidence of residual disease. Participants with    │         │
│ nonmelanoma skin cancer or carcinoma in situ of    │ non-melanoma skin cancer or carcinoma in situ of   │         │
│ any type are not excluded if they have undergone   │ any type are not excluded if they have undergone   │         │
│ complete resection                                 │ complete resection                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has greater than or equal to (\>=) Grade 2         │ Has greater than or equal to (>=) Grade 2          │     100 │
│ peripheral neuropathy, or Grade 1 with pain on     │ peripheral neuropathy, or Grade 1 with pain on     │         │
│ clinical examination during the screening period   │ clinical examination during the screening period   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ PD on first-line therapy                           │ PD on first-line therapy                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Central nervous system involvement by MM           │ Central nervous system involvement                 │      92 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Failure to have fully recovered (that is, less     │ Failure to have fully recovered (that is, less     │      99 │
│ than or equal to \[\<=\] Grade 1 toxicity) from    │ than or equal to [<=] Grade 1 toxicity) from the   │         │
│ the reversible effects of prior chemotherapy       │ reversible effects of prior chemotherapy           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Female participants who                            │ Central nervous system involvement                 │      32 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Major surgery within 14 days before enrollment     │      33 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Are surgically sterile, OR                         │ Major surgery within 14 days before enrollment     │      39 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ o Stem cell harvest and mobilization regimen is    │ Participants must have completed 3 cycles of a     │      40 │
│ acceptable if clinically indicated, but must first │ bortezomib-based induction regimen (as defined by  │         │
│ be confirmed by the Takeda Medical Monitor         │ current NCCN guidelines) and have no evidence of   │         │
│                                                    │ disease progression as defined by IMWG criteria    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Are postmenopausal for at least 1 year before the  │ Major surgery within 14 days before enrollment     │      42 │
│ screening visit, OR                                │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If they are of childbearing potential, agree to    │ Infection requiring systemic antibiotic therapy or │      42 │
│ practice 2 effective methods of contraception, at  │ other serious infection within 14 days before      │         │
│ the same time, from the time of signing the        │ study enrollment                                   │         │
│ informed consent form through 90 days after the    │                                                    │         │
│ last dose of study drug, OR                        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Agree to practice effective barrier contraception  │ Infection requiring systemic antibiotic therapy or │      43 │
│ during the entire study treatment period and       │ other serious infection within 14 days before      │         │
│ through 90 days after the last dose of study drug, │ study enrollment                                   │         │
│ OR                                                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have previously been treated with ixazomib, or     │ Radiotherapy within 14 days before enrollment (if  │      43 │
│ participated in a study with ixazomib whether      │ the involved field is small, 7 days will be        │         │
│ treated with ixazomib or not                       │ considered a sufficient interval between treatment │         │
│                                                    │ and administration of the ixazomib.)               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Agree to practice true abstinence when this is in  │ Diagnosed or treated for another malignancy within │      45 │
│ line with the preferred and usual lifestyle of the │ 2 years before study enrollment or previously      │         │
│ participant (periodic abstinence \[example,        │ diagnosed with another malignancy and have any     │         │
│ calendar, ovulation, symptothermal, post-ovulation │ evidence of residual disease. Participants with    │         │
│ methods\] and withdrawal are not acceptable        │ non-melanoma skin cancer or carcinoma in situ of   │         │
│ methods of contraception)                          │ any type are not excluded if they have undergone   │         │
│                                                    │ complete resection                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Agree to practice true abstinence when this is in  │ Diagnosed or treated for another malignancy within │      45 │
│ line with the preferred and usual lifestyle of the │ 2 years before study enrollment or previously      │         │
│ participant. (Periodic abstinence (example,        │ diagnosed with another malignancy and have any     │         │
│ calendar, ovulation, symptothermal, post-ovulation │ evidence of residual disease. Participants with    │         │
│ methods\] and withdrawal are not acceptable        │ non-melanoma skin cancer or carcinoma in situ of   │         │
│ methods of contraception)                          │ any type are not excluded if they have undergone   │         │
│                                                    │ complete resection                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have a diagnosis of a MM using current IMWG   │ Failure to have fully recovered (that is, less     │      46 │
│ diagnostic criteria and have received 1 prior line │ than or equal to [<=] Grade 1 toxicity) from the   │         │
│ of therapy                                         │ reversible effects of prior chemotherapy           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must be transplant ineligible as determined by     │ Participants must be considered by their physician │      47 │
│ their physician, or if transplant eligible, not    │ eligible to receiving the IRD regimen              │         │
│ expect to undergo transplant for at least 24       │                                                    │         │
│ months after study enrollment                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male participants, even if surgically sterilized   │ Failure to have fully recovered (that is, less     │      47 │
│ (that is, status post-vasectomy), must agree to    │ than or equal to [<=] Grade 1 toxicity) from the   │         │
│ one of the following                               │ reversible effects of prior chemotherapy           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 66
Average Levenshtein Ratio of individual lines: 73.62068965517241
OverAll Ratio: 69.8103448275862
